Aura Biosciences (NASDAQ:AURA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Aura Biosciences (NASDAQ:AURA) released its earnings results on Tuesday. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA opened at $10.33 on Thursday. The business has a 50 day simple moving average of $9.75 and a 200 day simple moving average of $8.50. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The stock has a market cap of $512.47 million, a price-to-earnings ratio of -5.97 and a beta of 0.33.

Analyst Upgrades and Downgrades

AURA has been the subject of several research reports. Scotiabank raised their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. HC Wainwright raised their target price on shares of Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, BTIG Research lifted their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $23.00.

Insider Activity at Aura Biosciences

In other news, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now owns 134,276 shares in the company, valued at $1,615,340.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO Julie B. Feder sold 25,131 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now directly owns 134,276 shares in the company, valued at approximately $1,615,340.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Mark Plavsic sold 7,383 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,259 shares of company stock valued at $780,699. 5.40% of the stock is currently owned by corporate insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.